Regulatory News

CE certification for HIV screening kit

Mar 23, 2012

RNS Number : 9058Z
BATM Advanced Communications Ld
23 March 2012

BATM Advanced Communications Limited

CE certification for HIV screening kit

BATM Advanced Communications Limited ("the Company") (LSE: BVC), a leading designer and producer of broadband data and telecoms systems and medical laboratory equipment, is delighted to announce that its fully owned subsidiary Adaltis, a manufacturer of medical diagnostics equipment, has received CE certification for its Detect HIV 4th generation (AIDS 4th generation ) Total Screening Kit.

The kit is able to detect simultaneously HIV 1&2 antibodies and HIV p24 antigens, with the 4th generation screening able to detect the latest strains of the virus. Testing in external, independent labs has shown performance results of 100% accuracy for diagnostic sensitivity and 99.7% for diagnostic specifity, clearly marking this screening kit as the top of its class. This level of accuracy will ensure that patients receive reliable diagnosis and that laboratories are spared the significant and needless expense of repeat testing.

Initial deliveries of the new kit will start in the second quarter of this year, with an increasing buildup of production through the fourth quarter and into next year.

Dr Zvi Marom, Chief Executive, of BATM commented:

"The sensitivity and specifity performance levels of our Total Screening Kit are clearly outstanding and we are delighted to have received CE certification. We have received great interest in this product and certification now allows us to increase sales in several territories.

"This important step in our medical division augurs well for its future with the prospect of improved margins and sales. The Company is encouraged that its success with this kit will extend to other kits that are under certifications."

- Ends -

For further information:


BATM Advanced Communications +972 9866 2527
Ofer Bar-Ner, CFO

Newgate Threadneedle 020 7653 9850
Josh Royston / Graham Herring

finnCap 020 7220 0500
Marc Young / Brian Patient

Shore Capital 020 7408 4090
Pascal Keane

Notes to Editors

According to a report in January 2012 from, there are an estimated 33.3 million people living with HIV worldwide and approximately 2.6 million people are newly infected each year. Although the Asian and African regions account for more than 90% of the HIV-infected population, the U.S. and European regions make up greater than 60% of the HIV testing market.

The same report also states that the global HIV-AIDS testing market is forecasted to catapult to $4.4 billion by 2016.

This information is provided by RNS
The company news service from the London Stock Exchange